Tarceva: profile and news
Tarceva Alone Has Palliative Effects in Patients With Metastatic ... 16 May 2006
Researchers from Canada have reported that Tarceva (erlotinib) alone produces disease stabilization lasting a median of 8 weeks in 39% of patients with ... - Cancer Consultants (press release),
UPDATE 1-OSI quarterly loss narrows on Tarceva, Macugen May 8, 2006
...ago quarter. The company reported its share of revenue from Tarceva, the lung cancer drug its co-promotes with Genentech Inc. (DNA ... - Reuters
Roche launches Tarceva for lung cancer May 8, 2006
Roche Scientific Company announced that the innovative drug, Tarceva (erlotinib) will be available in India. Tarceva brings a glimmer ... - Express Pharma,
OSI Pharma looking for Japan Tarceva OK Apr 17, 2006
...said Monday that its international marketing partner for the cancer drug Tarceva submitted a marketing application to get the drug approved in Japan. ... - BusinessWeek
Osi says Roche's Chugai filed new drug application for Tarceva in ... Apr 17, 2006
Co, a Japanese affiliate of Roche Holding AG has filed a new drug application for its lung cancer medication and flagship product Tarceva in Japan. ... - Forbes
OSI Pharmaceuticals Announces Submission of New Drug Application ... Apr 17, 2006
...(Nasdaq: OSIP) announced today that a New Drug Application has been submitted in Japan covering the use of its flagship product, Tarceva(R) (erlotinib), for ... - International News Service,
OSI files for Japanese Tarceva approval Apr 19, 2006
OSI Pharmaceuticals has submitted a new drug application in Japan covering the use of Tarceva in advanced or recurrent non-small cell lung cancer. ... - Pharmaceutical Business Review
OSI applies to sell Tarceva drug in Japan Apr 17, 2006
OSI Pharmaceuticals Inc., the Melville-based healthcare company, said this morning it has applied to sell its flagship Tarceva product in Japan. ... - Newsday,
OSI Pharma Submits NDA For Cancer Drug Tarceva In Japan - Quick ... Apr 17, 2006
...(RTTNews) - OSI Pharmaceuticals, Inc. (OSIP | charts | news | PowerRating) submitted a New Drug Application in Japan for Tarceva, or erlotinib, for the ... - Trading Markets,
Xeloda®, Eloxatin® and Tarceva® Effective for Previously ... Apr 28, 2006
Dana Farber Cancer Center have reported that the combination of oral Xeloda (capecitabine), intravenous Eloxatin (oxaliplatin) and oral Tarceva (erlotinib) is ... - Cancer Consultants (press release),
Xeloda®, Eloxatin®, and Tarceva® Effective for Previously ... Apr 19, 2006
...in the Journal of Clinical Oncology, the treatment combination consisting of Xeloda® (capecitabine), Eloxatin® (oxaliplatin), and Tarceva® (erlotinib) is an ... - Cancer Consultants (press release),
Multicenter Trial Confirms That Nexavar® Has Significant Activity ... May 15, 2006
The combination of Tarceva® (erlotinib) plus Avastin® (bevacizumab) has also shown activity in the treatment of metastatic renal cell carcinoma. ... - Cancer Consultants (press release),
OSI Submits New Drug Application For Tarceva In Japan Apr 17, 2006
...(OSIP) Monday filed a new drug application in Japan for its flagship product, Tarceva, which has been approved in the US, Europe, and about 50 other countries. ... - Therapeutics Daily (subscription) (press release),
OSI Pharmaceuticals Announces Submission of New Drug Application ... Apr 17, 2006
...(Nasdaq: OSIP) announced todaythat a New Drug Application has been submitted in Japan covering theuse of its flagship product, Tarceva(R) (erlotinib), for the ... - Finanzen.net,
OSI Pharmaceuticals Announces First Quarter 2006 Financial Results May 8, 2006
The increase is primarily due to the growth in revenues arising from worldwide Tarceva(R) (erlotinib) sales, and Macugen(R) (pegaptanib sodium injection ... - Genetic Engineering News,
OSI Pharmaceuticals Announces First Quarter 2006 Financial Results May 8, 2006
...to revenues of $19.1 million for the first quarter of 2005.The increase is primarily due to the growth in revenues arising fromworldwide Tarceva(R) (erlotinib ... - Finanzen.net,
New lung cancer treatment study May 14, 2006
Tarceva is another approved drug for the treatment of patients with lung cancer who have failed at least one chemotherapy regimen. ... - New York Daily News,
No better drug bargain May 15, 2006
That includes such miracle cancer drugs such as Gleevec and Tarceva. As a result, people not only get sicker under the VA program, they die sooner as well. ... - Washington Times,
OSI Pharmaceuticals Reports Profits In Q1, On Adjusted Basis, As ... May 8, 2006
The revenues for the quarter soared more than 500% driven by worldwide sales of Tarceva and Macugen sales, but missed the consensus revenue estimate of the ... - Trading Markets,
OSI cuts its losses May 9, 2006
...reported Monday that its first-quarter losses fell to $17.9 million, or 31 cents per share, because of higher sales of its cancer drug Tarceva. ... - Long Island Business News (subscription),
Genentech Announces Vice President Appointments in Commercial ... May 11, 2006
In this role, Miller will be responsible for leading all sales and marketing activities for Herceptin(R) (Trastuzumab) and Tarceva(R) (erlotinib). ... - Finanzen.net,
Mixed Results for OSI May 8, 2006
...in revenue during the quarter, more than five times its top line in the same period a year ago, thanks to sales of its lung-cancer drug Tarceva, which was co ... - TheStreet.com
Pharma Companies Advised To Build Buzz Before FDA Approval May 3, 2006
For the study, Nielsen BuzzMetrics compared discussions at online communities about four drugs--cancer treatments Abraxane and Tarceva, diabetes drug Byetta ... - MediPost Publications,
Patient is loser in postcode lottery May 3, 2006
Paul is fighting to be prescribed the cancer drug Tarceva, which could prolong his life by up to three years, but health bosses say the drug is "not cost ... - Morecambe Today,
YOU CAN'T HAVE LIFE-SAVER DRUG YOU CAN HAVE A pounds 9,000 NEW CAR May 7, 2006
Terminally-ill Paul Bould was told by his health authority he could not have new drug Tarceva because it was "not cost effective". ... - Therapeutics Daily (subscription) (press release),
OSI Pharmaceuticals to Present at the Bank of America Health Care ... May 9, 2006
OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have ... - Genetic Engineering News,
Chugai Shares Post Healthy Gain On Prospects for Cancer Drug May 9, 2006
Chugai has filed for approval of Tarceva, a lung-cancer drug developed by Genentech and OSI Pharmaceuticals of Melville, New York. ... - Wall Street Journal,
OSI's Macugen Still Burdened By Lucentis Threat May 10, 2006
OSI and Genentech are partners on cancer drug Tarceva, OSI's other top-selling drug. Farmer expects the companies to report data ... - Forbes
Deaths from lung cancer increase in women May 3, 2006
...and in women, cause lung cancer patients with these abnormalities to respond better to the newer, targeted cancer therapies such as Iressa and Tarceva. ... - South Bend Tribune,
AV-412 demonstrates potent antitumor activity in preclinical ... May 2, 2006
...models, its anticancer compound AV-412 demonstrated potent antitumor activity against tumors that were sensitive to treatment with Tarceva (erlotinib) and ... - Therapeutics Daily (subscription) (press release),
OSI to expand directors board Apr 21, 2006
OSI is currently marketing Tarceva, its flagship product aimed at treating lung cancer. The company got a major boost two years ... - Newsday,
Genta Incorporated Announces First Quarter 2006 Financial Results ... May 9, 2006
Genasense has demonstrated preclinical synergy with various treatments, such as Tarceva(R) (erlotinib; OSI Pharmaceuticals), interferon and radiation, that ... - International News Service,
Park Electrochemical doubles its profits May 9, 2006
...for the quarter ended March 31, from $19.1 million in the same period last year, driven in part by expansion of worldwide sales of its cancer treatment Tarceva ... - Newsday,
Pre-Launch Internet Buzz for New Drugs Can Lead to Greater Online ... May 2, 2006
The drugs were Abraxane and Tarceva, both cancer-fighting drugs; Tysabri, for treating multiple sclerosis (voluntarily suspended from the market in October ... - Market Wire (press release)
Monogram Announces First Quarter 2006 Financial Results May 8, 2006
Herceptin is a registered trademark of Genentech, Inc., Tarceva is a trademark of OSI Pharmaceuticals, Inc., Erbitux is a trademark of ImClone Systems ... - Yahoo! News (press release)
Subsidising high-cost drugs a matter of life, not death Apr 22, 2006
...that use genetic information to slow or stop the spread of cancers; they include Herceptin for breast cancer, Avastin for bowel cancer and Tarceva for lung ... - The Age,
Roche Off-Target But Guidance Raised -Lehman Apr 26, 2006
...expectations. "Sales for Herceptin, Avastin and Tarceva all beat but NeoRecormon and 'other' were light of our estimates," analyst says. ... - newratings.com
OSI Pharmaceuticals to Present at the Bank of America Health Care ... May 9, 2006
OSI'sflagship product, Tarceva(R) (erlotinib), is the first drug discoveredand developed by OSI to obtain FDA approval and the only EGFRinhibitor to have ... - Finanzen.net,
UPDATE: Roche Revenue Climbs 22% On Cancer Drugs, Tamiflu Apr 26, 2006
...trading. Sales of its cancer drug portfolio -- Herceptin, Avastin, MabThera, Tarceva and Xeloda -- jumped 52%, with the majority ... - Therapeutics Daily (subscription) (press release),
Roche Showed Continued Strong Sales Growth in the First Quarter ... Apr 26, 2006
...s oncology portfolio, which showed again a significant increase in sales for all its key products, including Herceptin, Avastin, MabThera, Tarceva and Xeloda. ... - PharmaLive.com (press release),
Fighting Cancer: Startup Pique Therapeutics’ Lead Drug Candidate ... May 1, 2006
Even Tarceva, a recent success story for cancer therapeutics, only extended median survival of late-stage NSCLC patients from 4.7 months to 6.7 months. ... - Local Tech Wire,
Herceptin delivers record sales for Swiss drugs giant Apr 26, 2006
However, the fastest growth was achieved by Tarceva, which has been proved to prolong the lives of nearly half of patients suffering late-stage lung cancer by ... - Times Online,
Swiss shares lower midmorning on US, oil, led down by insurers ... Apr 18, 2006
Co said it has filed a new drug application for the treatment of advanced or recurrent non-small cell lung cancer of its flagship product Tarceva in Japan. ... - Forbes
Chugai seeks Japan approval for lung cancer drug Apr 16, 2006
...unit of Switzerland's Roche Holding AG (ROG.VX: Quote, Profile, Research), said on Monday it has filed for approval for the lung cancer drug Tarceva in Japan. ... - Reuters
Roche's Chugai unit files cancer drug Avastin for fast approval in ... Apr 21, 2006
..."Today's submission comes just after Tarceva's initial filing in advanced or recurrent non-small cell lung cancer and represents a further significant ... - MarketWatch
Genentech's Avastin To Spark Upside Potential Apr 26, 2006
In addition, mid-stage data for Avastin and Tarceva combination therapy is expected in June at the annual meeting for the American Society of Oncologists, or ... - Forbes
Roche Q1 sales ahead of consensus, sticks to FY guidance UPDATE Apr 25, 2006
...were the company''s oncology drugs, sales of which soared a combined 52 pct in the period year-on-year, such as Herceptin, Avastin, MabThera, Tarceva and Xeloda ... - Euro2day,
��：生命�纬 Apr 27, 2006
OSI Pharmaceuticals whose growth engine is the cancer drug Tarceva, generated a firestorm of opposition from shareholders when it acquired Eyetech ... - BioX,
Chugai Files NDA For An Anti-Tumor Agent, Erlotinib (Epidermal ... Apr 18, 2006
...cell. Currently, erlotinib is marketed in more than 50 countries including the US and Europe, under the product name of Tarceva(R). ... - Medical News Today (press release),
Chugai files innovative cancer medicine Avastin for fast approval ... Apr 21, 2006
...“Today’s submission comes just after Tarceva’s initial filing in advanced or recurrent non-small cell lung cancer and represents a further significant ... - WebWire (press release),
